Bringing together 150+ leaders and 46+ speakers from AbbVie, Lundbeck, COMPASS Pathways, Karuna Therapeutics, and more to advance neuropsychiatric drug development — covering schizophrenia, depression, PTSD, addiction, and beyond. Sessions focus on EEG/digital biomarkers, patient stratification, and novel endpoints, plus dedicated pre-conference workshop days. Organized by Hanson Wade.